Jun 5 |
Gilead progresses subject enrolment in HIV prevention trials
|
Jun 5 |
J&J seeks expanded approvals for paediatric HIV-1 therapy
|
Jun 5 |
Gilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis
|
Jun 4 |
National Institutes of Health Kickstarts Gilead Sponsored Trials For Twice-Yearly HIV Prevention Injection
|
Jun 4 |
Sector Update: Health Care Stocks Rise Tuesday Afternoon
|
Jun 4 |
The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
|
Jun 4 |
3 Dividend Stocks That Even Ken Griffin Is Buying
|
Jun 3 |
Hedge Funds are Bullish on This Gene Therapy Stock
|
Jun 3 |
Gilead, Arcus combo significantly reduces death risk in colorectal cancer
|
Jun 3 |
Gilead (GILD), RCUS Announce Data From Colorectal Cancer Study
|